Explore AstraZeneca PLC's latest Form 6-K, filed on August 1, 2025, detailing 1.55B voting rights and compliance with UK regulations vital for shareholders.
Explore AstraZeneca's Q2 2025 financial report, highlighting $28.045B revenue, 8% growth, and a strong investment recommendation.
AstraZeneca announces EU approval of Imfinzi for muscle-invasive bladder cancer, showing significant survival benefits and addressing critical treatment needs.
Discover AstraZeneca's total voting rights and regulatory compliance in the July 2025 report, vital for shareholders and investor relations.
AstraZeneca PLC announces the approval of Datroway for advanced EGFR-mutated lung cancer, highlighting clinical trial success and strategic collaboration with Daiichi Sankyo.
AstraZeneca's 6-K filing reveals EU approval for Calquence in CLL, showcasing superior trial results and market potential.
Explore AstraZeneca PLC's Form 6-K detailing issued share capital, total voting rights, and regulatory compliance for investors and analysts.
Discover AstraZeneca's June 2025 Block Listing Interim Review, detailing securities management and share option plans. Key insights on compliance and financial performance.
AstraZeneca's report highlights Imfinzi's EU approval for muscle-invasive bladder cancer, showcasing significant efficacy from clinical trials. Key insights reveal its potential to redefine treatment standards.
AstraZeneca's Form 6-K reveals CEO Pascal Soriot's acquisition of 8,970 shares post-vesting. Key insights on performance, compliance, and tax obligations included.
AstraZeneca PLC's May 2025 Form 6-K details CEO Pascal Soriot's appointment to Agilent Technologies. Explore key insights on leadership changes and regulatory compliance.
Explore Gilead Sciences' Q1 2025 financial report, highlighting $6.647B revenue, $1.315B net income, and a positive outlook for investors. Key insights on profitability and R&D investments.